Business UpdateMay 27, 2026, 07:06 AM
Satellos Bioscience to Present at June Investor Conferences
AI Summary
Satellos Bioscience Inc. announced its participation in two investor conferences in June 2026. The company will present at the Jefferies Global Healthcare Conference on June 4 and join a panel at the Oppenheimer CNS & Neuro-Muscular Summit on June 10. Members of the leadership team will also be available for one-on-one investor meetings, and the presentation will be webcast live with a replay available afterward. Satellos is a clinical-stage drug development company focused on SAT-3247 for degenerative muscle diseases like DMD.
Key Highlights
- Satellos Bioscience will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:05 a.m. in New York, NY.
- The company will participate in a panel at the Oppenheimer CNS & Neuro-Muscular Summit on June 10, at 10:15 a.m. in Miami, FL.
- The presentation will be available via live webcast on the Investors section of the Company website.
- A replay of the presentation will be available following the event.
- Satellos leadership will be available for one-on-one investor meetings during both conferences.
- Satellos is a clinical-stage drug development company advancing SAT-3247 for degenerative muscle diseases, initially for DMD.
- SAT-3247 is being evaluated in two Phase II clinical trials: BASECAMP (pediatrics) and TRAILHEAD (adults).
Price Impact
More from MSLE